Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Acerta Pharma B.V.
Headquarters: Oss, Netherlands
Website: http://www.acerta-pharma.com...
Year Founded: 2012
Status: Private
BioCentury | Nov 4, 2024
Distillery Therapeutics
Inhibiting BTK or CD84 for alcohol-associated hepatitis
BioCentury | Sep 29, 2022
Management Tracks
Kevin Bunker promoted to CSO at Zentalis
Plus Fonck becomes partner at Pureos, and updates from 4D Molecular, Gandeeva, Code and more
BioCentury | Feb 8, 2022
Management Tracks
Lander resigns as Biden’s science adviser
Plus CMO Michaels out at Editas and updates from Tmunity, StrideBio, Adverum, iOmx, Curie and more
BioCentury | Jan 25, 2022
Management Tracks
Braunstein now CMO at Idorsia
Plus Kush, Haddach join RayzeBio and updates from Coherus, InterVenn, AsherBio and more
BioCentury | Jan 8, 2021
Finance
More strategics pile into Dutch early-stage investor BGV’s largest-ever fund
€140 million fourth fund gains new strategic backers Lilly, Novo Ventures
BioCentury | Sep 23, 2020
Management Tracks
Gilead BD head Bender takes top job at pediatric cancer start-up Day One
Bowers to head commercial as Canaan-incubated biotech builds out team
BioCentury | Jul 11, 2020
Management Tracks
Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more
BioCentury | Jun 24, 2020
Finance
Expect more company creation by BGV with its €105M fourth fund
Dutch VC BioGeneration Ventures expects to create half of the European start-ups backed by new fund
BioCentury | Dec 9, 2019
Company News
With $2.7B ArQule buyout, Merck is latest pharma to jump into Btk race
BioCentury | Nov 15, 2019
Company News
BeiGene enters U.S. market with first approval for in-house pipeline
Items per page:
1 - 10 of 38